Envista Holdings earnings release, August 5, 2026
Envista Reports Second Quarter 2026 Results
BREA, Calif., August 5, 2026 /
PRNewswire
/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended July 3, 2026.
“We built on our fast start in Q1 with continued good performance in Q2,” said Paul Keel, CEO. “We delivered growth across both our reporting segments and all major geographies. Our focus on operational excellence, underpinned by the Envista Business System, contributed to further margin expansion. Based on our strong first-half performance and continued momentum, we are raising our full year outlook for core sales growth, adjusted EBITDA, and adjusted EPS. We are well-positioned to deliver another year of progress and performance.”
Second Quarter Financial Highlights
• Sales were $731 million, with core sales growth of 5.0% over the second quarter of 2025.
• GAAP diluted EPS of $0.33 and adjusted diluted EPS of $0.41 (+58% year-on-year)
• GAAP Net Income of $54 million and adjusted EBITDA of $108 million (+28% year-on-year), with an adjusted EBITDA margin of 14.7% (+230 bps year-on-year)
Second Quarter Business Highlights
• Growth:
In the context of macro uncertainty, both reporting segments delivered positive growth, with 3.1% core growth in Specialty Products & Technologies and 8.5% core growth in Equipment and Consumables.
• Operations:
Ongoing contributions from the Envista Business System (EBS) supporting 70 bps of adjusted gross margin and 230 bps of adjusted EBITDA margin expansion.
• People: Continued to advance our high-performing, continuous improvement culture through numerous customer, employee, and charitable events around the world.
Net Income, EBITDA, and EPS
(in millions, except per share amounts)
:
Cash Flow:
Operating cash flow for the second quarter of 2026 was $119 million and free cash flow was $105 million, compared to $89 million and $76 million in the second quarter of 2025, respectively.
Share Repurchases:
During the quarter ended July 3, 2026, we repurchased 2.4 million shares for approximately $59 million. At the end of the quarter, we had approximately $283 million remaining repurchase capacity under our stock repurchase program.¹
Outlook:
We are updating our guidance for the full year 2026:
Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.
We will discuss our quarterly results and provide details on our outlook for 2026 during an investor conference call on August 5, 2026, starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of our website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of our website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by dialing 800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #73468.
A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of our website under the subheading "Events & Presentations." Presentation materials relating to our results have been posted to the "Investors" section of our website under the subheading "Quarterly Earnings".
ABOUT ENVISTA
Envista is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients’ lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care—today and for the future. Learn more at http://envistaco.com.²
NON-GAAP MEASURES
All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure.
Financial statements
Income Statement
Three Months Ended — :
| Three Months Ended – July 3, 2026 | Three Months Ended – June 27, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – June 27, 2025 | |
|---|---|---|---|---|
| GAAP Net Income | 54 | 26 | 92 | 44 |
| Adjusted Net Income | 67 | 44 | 126 | 85 |
| Adjusted EBITDA | 108 | 84 | 207 | 163 |
| GAAP Diluted Earnings Per Share | 0.33 | 0.16 | 0.56 | 0.26 |
| Adjusted Diluted Earnings Per Share | 0.41 | 0.26 | 0.77 | 0.5 |
Income Statement
Core Sales Growth — We are updating our guidance for the full year 2026:
| Current 2026 Guidance | Prior 2026 Guidance | |||
|---|---|---|---|---|
| Core Sales Growth | 3.5% to 4.5% | 2% to 4% | ||
| Adjusted EBITDA Growth | 11% to 14% | 7% to 13% | ||
| Adjusted Diluted Earnings Per Share | $1.50 to $1.55 | $1.35 to $1.45 | ||
| Free Cash Flow Conversion | ~100% | ~100% |
Income Statement
Three Months Ended — ($ and shares in millions, except per share amounts)
| Three Months Ended – July 3, 2026 | Three Months Ended – June 27, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – June 27, 2025 | ||
|---|---|---|---|---|---|
| Sales | 730.5 | 682.1 | 1,436 | 1,299 | |
| Cost of sales | 323.5 | 312.2 | 638.9 | 593.1 | |
| Gross profit | 407 | 369.9 | 797.1 | 705.9 | |
| Operating expenses: | Selling, general and administrative | 296.3 | 295.3 | 593.9 | 567 |
| Operating expenses: | Research and development | 30.4 | 28.3 | 60.4 | 53.6 |
| Operating expenses: | Operating profit | 80.3 | 46.3 | 142.8 | 85.3 |
| Nonoperating (expense) income: | Other income (expense), net | 2.8 | 2.4 | -0.1 | 1.7 |
| Nonoperating (expense) income: | Interest expense, net | -8.7 | -8 | -16.1 | -17.3 |
| Nonoperating (expense) income: | Income before income taxes | 74.4 | 40.7 | 126.6 | 69.7 |
| Nonoperating (expense) income: | Income tax expense | 20.7 | 14.3 | 34.2 | 25.3 |
| Nonoperating (expense) income: | Net income | 53.7 | 26.4 | 92.4 | 44.4 |
| Earnings per share: | Earnings - basic | 0.33 | 0.16 | 0.57 | 0.26 |
| Earnings per share: | Earnings - diluted | 0.33 | 0.16 | 0.56 | 0.26 |
| Average common stock and common equivalent shares outstanding: | Basic | 161.9 | 169 | 162.9 | 170.7 |
| Average common stock and common equivalent shares outstanding: | Diluted | 164.1 | 169.9 | 165.3 | 171.7 |
Income Statement
Three Months Ended — ($ in millions, except per share amounts)
| Three Months Ended – July 3, 2026 – GAAP | Three Months Ended – June 27, 2025 – GAAP | Six Months Ended – July 3, 2026 – GAAP | Six Months Ended – June 27, 2025 – GAAP | |
|---|---|---|---|---|
| Gross Profit | 407 | 369.9 | 797.1 | 705.9 |
| Operating Profit | 80.3 | 46.3 | 142.8 | 85.3 |
| Net Income | 53.7 | 26.4 | 92.4 | 44.4 |
| Diluted Earnings Per Share | 0.33 | 0.16 | 0.56 | 0.26 |
| Operating Cash Flow | 119.2 | 88.7 | 115.9 | 89 |
Income Statement
($ in millions, except per share amounts)
| NON-GAAP * – Three Months Ended – July 3, 2026 | NON-GAAP * – Three Months Ended – June 27, 2025 | NON-GAAP * – Six Months Ended – July 3, 2026 | NON-GAAP * – Six Months Ended – June 27, 2025 | |
|---|---|---|---|---|
| Adjusted Gross Profit | 402.2 | 371.2 | 795.8 | 709.5 |
| Adjusted Operating Profit | 94.5 | 71.1 | 183.9 | 141.7 |
| Adjusted Net Income | 66.5 | 43.7 | 126.5 | 85.2 |
| Adjusted Diluted EPS | 0.41 | 0.26 | 0.77 | 0.5 |
| Adjusted EBITDA | 107.7 | 84.3 | 206.6 | 163.3 |
| Free Cash Flow | 105.1 | 76.4 | 89.4 | 71.3 |
Income Statement
Three Months Ended — Adjusted Gross Profit and Adjusted Gross Margin
| Three Months Ended – July 3, 2026 | Three Months Ended – June 27, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – June 27, 2025 | |
|---|---|---|---|---|
| Gross Profit | 407 | 369.9 | 797.1 | 705.9 |
| Restructuring costs and asset impairments A | 7.3 | 0.3 | 10.4 | 2.2 |
| Fair value adjustment of acquisition-related inventory B | 0.5 | 1 | 0.9 | 1.4 |
| Tariff refunds C | -12.6 | -12.6 | ||
| Adjusted Gross Profit | 402.2 | 371.2 | 795.8 | 709.5 |
| Gross Margin (Gross Profit / Sales) | 55.7 | 54.2 | 55.5 | 54.3 |
| Adjusted Gross Margin (Adjusted Gross Profit / Sales) | 55.1 | 54.4 | 55.4 | 54.6 |
Income Statement
Three Months Ended — Adjusted Diluted Earnings Per Share
| Three Months Ended – July 3, 2026 | Three Months Ended – June 27, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – June 27, 2025 | |
|---|---|---|---|---|
| Diluted Earnings Per Share | 0.33 | 0.16 | 0.56 | 0.26 |
| Amortization of acquisition-related and other intangible assets | 0.11 | 0.11 | 0.22 | 0.22 |
| Restructuring costs and asset impairments A | 0.05 | 0.03 | 0.1 | 0.09 |
| Fair value adjustment of acquisition-related inventory B | 0.01 | 0.01 | 0.01 | |
| Tariff refunds C | -0.08 | -0.08 | ||
| Litigation settlement D | 0.01 | |||
| Loss on equity investments F | 0.01 | |||
| Tax effect of adjustments reflected above G | -0.01 | -0.04 | -0.06 | -0.09 |
| Discrete tax adjustments and other tax-related adjustments H | 0.01 | -0.01 | 0.01 | |
| Adjusted Diluted Earnings Per Share | 0.41 | 0.26 | 0.77 | 0.5 |
Income Statement
Three Months Ended — Adjusted EBITDA
| Three Months Ended – July 3, 2026 | Three Months Ended – June 27, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – June 27, 2025 | |
|---|---|---|---|---|
| Net Income | 53.7 | 26.4 | 92.4 | 44.4 |
| Interest expense, net | 8.7 | 8 | 16.1 | 17.3 |
| Income tax expense | 20.7 | 14.3 | 34.2 | 25.3 |
| Depreciation | 10.4 | 10.8 | 20.8 | 19.9 |
| Amortization of acquisition-related and other intangible assets | 17.4 | 19 | 36.2 | 37.8 |
| Restructuring costs and asset impairments A | 8.9 | 4.7 | 16.3 | 16.1 |
| Fair value adjustment of acquisition-related inventory B | 0.5 | 1 | 0.9 | 1.4 |
| Tariff refunds C | -12.6 | -12.6 | ||
| Litigation settlement D | 0.8 | |||
| Acquisition-related expenses E | 0.1 | 0.3 | 0.3 | |
| Loss on equity investments F | 2 | |||
| Adjusted EBITDA | 107.7 | 84.3 | 206.6 | 163.3 |
| Adjusted EBITDA as a % of Sales | 14.7 | 12.4 | 14.4 | 12.6 |
Balance Sheet
($ in millions, except share amounts)
| As of – July 3, 2026 | As of – December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 1,125.6 | 1,211.7 |
| Current assets: | Trade accounts receivable, less allowance for credit losses of $21.8 and $22.5, respectively | 436.9 | 429.6 |
Cash Flow
Six Months Ended — ($ in millions)
| Six Months Ended – July 3, 2026 | Six Months Ended – June 27, 2025 | ||
|---|---|---|---|
| Cash flows from operating activities: | Net income | 92.4 | 44.4 |
| Noncash items: | Depreciation | 20.8 | 19.9 |
| Noncash items: | Amortization | 36.2 | 37.8 |
| Noncash items: | Allowance for credit losses | 5.8 | 4 |
| Noncash items: | Stock-based compensation expense | 19.7 | 16.8 |
| Noncash items: | Gain on investments in rabbi trust, net | -1.9 | -1.6 |
| Noncash items: | Loss on equity investments | 2 | |
| Noncash items: | (Gain) loss on sale of property, plant and equipment | -2.7 | 0.3 |
| Noncash items: | Restructuring charges | 0.9 | 0.2 |
| Noncash items: | Fixed assets impairments and other charges | 0.9 | 1.4 |
| Noncash items: | Non-cash operating lease costs | 18.5 | 17.2 |
| Noncash items: | Amortization of debt discount and issuance costs | 2 | 2.2 |
| Noncash items: | Deferred income taxes | -0.9 | |
| Noncash items: | Change in trade accounts receivable | -14.5 | -37.2 |
| Noncash items: | Change in inventories | -0.9 | -23.5 |
| Noncash items: | Change in trade accounts payable | 0.1 | -10 |
| Noncash items: | Change in prepaid expenses and other assets | -7.3 | -4.3 |
| Noncash items: | Change in accrued expenses and other liabilities | -32.4 | 44.5 |
| Noncash items: | Change in operating lease liabilities | -23.7 | -22.2 |
| Noncash items: | Net cash provided by operating activities | 115.9 | 89 |
| Cash flows from investing activities: | Payments for additions to property, plant and equipment | -27.4 | -18.2 |
| Cash flows from investing activities: | Purchases of investments held in rabbi trust | -3.7 | -1 |
| Cash flows from investing activities: | Proceeds from sale of investments held in rabbi trust | 1.5 | 0.9 |
| Cash flows from investing activities: | Proceeds from sales of property, plant and equipment | 0.9 | 0.5 |
| Cash flows from investing activities: | Acquisitions, net of cash acquired | -54.4 | |
| Cash flows from investing activities: | All other investing activities, net | -0.1 | -8.1 |
| Cash flows from investing activities: | Net cash used in investing activities | -83.2 | -25.9 |
| Cash flows from financing activities: | Proceeds from stock option exercises | 4 | 1.5 |
| Cash flows from financing activities: | Cash paid for treasury stock under the stock repurchase program | -103 | -100.3 |
| Cash flows from financing activities: | Treasury stock purchases related to tax withholding on equity awards | -6.9 | -4.3 |
| Cash flows from financing activities: | Principal paid related to exchange of convertible notes due 2025 | -116.3 | |
| Cash flows from financing activities: | Proceeds from revolving line of credit | 115.4 | |
| Cash flows from financing activities: | All other financing activities | -0.4 | |
| Cash flows from financing activities: | Net cash used in financing activities | -106.3 | -104 |
| Cash flows from financing activities: | Effect of exchange rate changes on cash and cash equivalents | -12.5 | 82.4 |
| Cash flows from financing activities: | Net change in cash and cash equivalents | -86.1 | 41.5 |
| Cash flows from financing activities: | Beginning balance of cash and cash equivalents | 1,211.7 | 1,069.1 |
| Cash flows from financing activities: | Ending balance of cash and cash equivalents | 1,125.6 | 1,110.6 |
Cash Flow
Three Months Ended — Reconciliation of Operating Cash Flows to Free Cash Flow
| Three Months Ended – July 3, 2026 | Three Months Ended – June 27, 2025 | Six Months Ended – July 3, 2026 | Six Months Ended – June 27, 2025 | |
|---|---|---|---|---|
| Net operating cash (used in) provided by operating activities | 119.2 | 88.7 | 115.9 | 89 |
| Less: payments for additions to property, plant and equipment (capital expenditures) | -14.9 | -12.3 | -27.4 | -18.2 |
| Plus: proceeds from sales of property, plant and equipment | 0.8 | 0.9 | 0.5 | |
| Free Cash Flow (FCF) | 105.1 | 76.4 | 89.4 | 71.3 |
| FCF to Adjusted Net Income Conversion Ratio | 158 | 174.8 | 70.7 | 83.7 |
Full release
FORWARD-LOOKING STATEMENTS... (truncated)cies and regulations including tariffs or other impositions on imported goods, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war (including supply chain disruptions), terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, security breaches or other disruptions affecting our external information technology contractors, vendors or other service providers, our growing use of artificial intelligence systems to automate processes and analyze data, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to impairment charges for our goodwill and intangible assets, changes in accounting standards and subjective assumptions, estimates and judgment by management, currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2025 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
CONTACT
Jim Gustafson
Vice President, Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
IR@envistaco.com³